Literature DB >> 24325826

Type I interferon-dependent activation of NK cells by rAd28 or rAd35, but not rAd5, leads to loss of vector-insert expression.

Matthew J Johnson1, Niklas K Björkström2, Constantinos Petrovas3, Frank Liang4, Jason G D Gall5, Karin Loré4, Richard A Koup6.   

Abstract

Vaccines constructed from rare-serotype recombinant adenovirus vectors (rAd) such as rAd serotype 28 (rAd28) and rAd35 are currently being explored as alternatives to rAd5-based vaccines because they circumvent the problems with pre-existing immunity that complicate the effectiveness of rAd5 vaccines. However, previous work has demonstrated that the immunogenicity of rAd28 and rAd35 is substantially lower than rAd5. Here we show that rAd28 and rAd35 increase apoptosis of antigen presenting cells (APCs), such as monocytes, relative to rAd5 and mock infected controls. APCs undergoing apoptosis showed an increased loss of vector-insert expression. Loss of vector-insert expression correlated with activation of NK cells, which resulted in apoptosis of co-cultured monocytes. Finally, we show that activation of NK cells is dependent on IFNα which is produced by exposure to rAd28 or rAd35, but not to rAd5. Taken together, these data demonstrate that IFNα-induced activation of NK cells leads to increased monocyte apoptosis and subsequent vector-insert loss. This may be a possible mechanism that results in reduced immunogenicity of rAd28 and rAd35-based vectors. Published by Elsevier Ltd.

Entities:  

Keywords:  Adenovirus; rAd28; rAd35

Mesh:

Substances:

Year:  2013        PMID: 24325826      PMCID: PMC3946768          DOI: 10.1016/j.vaccine.2013.11.055

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  26 in total

1.  T cell sensing of antigen dose governs interactive behavior with dendritic cells and sets a threshold for T cell activation.

Authors:  Sarah E Henrickson; Thorsten R Mempel; Irina B Mazo; Bai Liu; Maxim N Artyomov; Huan Zheng; Antonio Peixoto; Michael P Flynn; Balimkiz Senman; Tobias Junt; Hing C Wong; Arup K Chakraborty; Ulrich H von Andrian
Journal:  Nat Immunol       Date:  2008-01-20       Impact factor: 25.606

2.  How antigen quantity and quality determine T-cell decisions in lymphoid tissue.

Authors:  Huan Zheng; Bo Jin; Sarah E Henrickson; Alan S Perelson; Ulrich H von Andrian; Arup K Chakraborty
Journal:  Mol Cell Biol       Date:  2008-04-21       Impact factor: 4.272

3.  Persistence of transgene expression influences CD8+ T-cell expansion and maintenance following immunization with recombinant adenovirus.

Authors:  Jonathan D Finn; Jennifer Bassett; James B Millar; Natalie Grinshtein; Teng Chih Yang; Robin Parsons; Carole Evelegh; Yonghong Wan; Robin J Parks; Jonathan L Bramson
Journal:  J Virol       Date:  2009-09-16       Impact factor: 5.103

4.  Potent immune responses and in vitro pro-inflammatory cytokine suppression by a novel adenovirus vaccine vector based on rare human serotype 28.

Authors:  Christoph A Kahl; Jessica Bonnell; Suja Hiriyanna; Megan Fultz; Cassandra Nyberg-Hoffman; Ping Chen; C Richter King; Jason G D Gall
Journal:  Vaccine       Date:  2010-06-29       Impact factor: 3.641

5.  Epitope density influences CD8+ memory T cell differentiation.

Authors:  Julie Leignadier; Nathalie Labrecque
Journal:  PLoS One       Date:  2010-10-29       Impact factor: 3.240

6.  Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial.

Authors:  Susan P Buchbinder; Devan V Mehrotra; Ann Duerr; Daniel W Fitzgerald; Robin Mogg; David Li; Peter B Gilbert; Javier R Lama; Michael Marmor; Carlos Del Rio; M Juliana McElrath; Danilo R Casimiro; Keith M Gottesdiener; Jeffrey A Chodakewitz; Lawrence Corey; Michael N Robertson
Journal:  Lancet       Date:  2008-11-13       Impact factor: 79.321

Review 7.  Adenovirus receptors: implications for tropism, treatment and targeting.

Authors:  Niklas Arnberg
Journal:  Rev Med Virol       Date:  2009-05       Impact factor: 6.989

8.  Apoptotic cells induce immunosuppression through dendritic cells: critical roles of IFN-gamma and nitric oxide.

Authors:  Guangwen Ren; Juanjuan Su; Xin Zhao; Liying Zhang; Jimin Zhang; Arthur I Roberts; Huatang Zhang; Gobardhan Das; Yufang Shi
Journal:  J Immunol       Date:  2008-09-01       Impact factor: 5.422

9.  Functional analysis of human NK cells by flow cytometry.

Authors:  Yenan T Bryceson; Cyril Fauriat; João M Nunes; Stephanie M Wood; Niklas K Björkström; Eric O Long; Hans-Gustaf Ljunggren
Journal:  Methods Mol Biol       Date:  2010

10.  Alternate serotype adenovector provides long-term therapeutic gene expression in the eye.

Authors:  Melissa M Hamilton; Gordon A Byrnes; Jason G Gall; Douglas E Brough; C Richter King; Lisa L Wei
Journal:  Mol Vis       Date:  2008-12-30       Impact factor: 2.367

View more
  11 in total

1.  Antigen expression determines adenoviral vaccine potency independent of IFN and STING signaling.

Authors:  Kylie M Quinn; Daniel E Zak; Andreia Costa; Ayako Yamamoto; Kathrin Kastenmuller; Brenna J Hill; Geoffrey M Lynn; Patricia A Darrah; Ross W B Lindsay; Lingshu Wang; Cheng Cheng; Alfredo Nicosia; Antonella Folgori; Stefano Colloca; Riccardo Cortese; Emma Gostick; David A Price; Jason G D Gall; Mario Roederer; Alan Aderem; Robert A Seder
Journal:  J Clin Invest       Date:  2015-02-02       Impact factor: 14.808

2.  Inhibition of type I interferon responses by adenovirus serotype-dependent Gas6 binding.

Authors:  Natalie F Nidetz; Tom M Gallagher; Christopher M Wiethoff
Journal:  Virology       Date:  2017-12-27       Impact factor: 3.616

3.  STAT2 Knockout Syrian Hamsters Support Enhanced Replication and Pathogenicity of Human Adenovirus, Revealing an Important Role of Type I Interferon Response in Viral Control.

Authors:  Karoly Toth; Sang R Lee; Baoling Ying; Jacqueline F Spencer; Ann E Tollefson; John E Sagartz; Il-Keun Kong; Zhongde Wang; William S M Wold
Journal:  PLoS Pathog       Date:  2015-08-20       Impact factor: 6.823

Review 4.  Methods and clinical development of adenovirus-vectored vaccines against mucosal pathogens.

Authors:  Sam Afkhami; Yushi Yao; Zhou Xing
Journal:  Mol Ther Methods Clin Dev       Date:  2016-04-27       Impact factor: 6.698

Review 5.  Development of Novel Adenoviral Vectors to Overcome Challenges Observed With HAdV-5-based Constructs.

Authors:  Julio Alonso-Padilla; Tibor Papp; Győző L Kaján; Mária Benkő; Menzo Havenga; Angelique Lemckert; Balázs Harrach; Andrew H Baker
Journal:  Mol Ther       Date:  2015-10-19       Impact factor: 11.454

6.  Adenovirus Vector Vaccination Impacts NK Cell Rheostat Function following Lymphocytic Choriomeningitis Virus Infection.

Authors:  Eryn Blass; Malika Aid; Amanda J Martinot; Rafael A Larocca; Zi Han Kang; Alexander Badamchi-Zadeh; Pablo Penaloza-MacMaster; R Keith Reeves; Dan H Barouch
Journal:  J Virol       Date:  2018-05-14       Impact factor: 5.103

7.  Skin immunisation activates an innate lymphoid cell-monocyte axis regulating CD8+ effector recruitment to mucosal tissues.

Authors:  Marija Zaric; Pablo D Becker; Catherine Hervouet; Petya Kalcheva; Andor Doszpoly; Negin Blattman; Lauren A O' Neill; Barbara Ibarzo Yus; Clement Cocita; Sung-Yun Kwon; Andrew H Baker; Graham M Lord; Linda S Klavinskis
Journal:  Nat Commun       Date:  2019-05-17       Impact factor: 14.919

8.  Differential immunogenicity between HAdV-5 and chimpanzee adenovirus vector ChAdOx1 is independent of fiber and penton RGD loop sequences in mice.

Authors:  Matthew D J Dicks; Alexandra J Spencer; Lynda Coughlan; Karolis Bauza; Sarah C Gilbert; Adrian V S Hill; Matthew G Cottingham
Journal:  Sci Rep       Date:  2015-11-18       Impact factor: 4.379

Review 9.  Pre-existing immunity against Ad vectors: humoral, cellular, and innate response, what's important?.

Authors:  Hugues Fausther-Bovendo; Gary P Kobinger
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

Review 10.  Advancing Immunotherapeutic Vaccine Strategies Against Pulmonary Tuberculosis.

Authors:  Sam Afkhami; Anne Drumond Villela; Michael R D'Agostino; Mangalakumari Jeyanathan; Amy Gillgrass; Zhou Xing
Journal:  Front Immunol       Date:  2020-09-09       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.